Number of the Day - 500 Cases

Key Takeaways

• KIRAMS Cancer Center completed 500 Revo-i surgeries.
• First Korean general hospital to reach 500 robot cases.
• Revo-i robot developed domestically by Meere Company.
• MOU provides technical consultation and clinical validation support.
• Milestone highlights expanding domestic surgical‑robot market.

Pulse Analysis

The global surgical‑robot market has been dominated for years by a handful of multinational firms, with systems such as da Vinci commanding premium prices that can exceed $2 million per unit. Hospitals seeking to adopt robotic assistance often face steep capital expenditures and ongoing service contracts, limiting diffusion in cost‑conscious health systems. In response, several countries have launched home‑grown platforms to lower entry barriers and retain intellectual property. South Korea, a leader in medical imaging and biotech, has invested heavily in domestic robotics to capture a share of this high‑growth segment.

Revo‑i, engineered by Meere Company, is Korea’s first fully indigenous surgical robot designed for minimally invasive oncology procedures. Since its introduction, the Korea Institute of Radiological & Medical Sciences (KIRAMS) Cancer Center has performed a steady stream of operations, culminating in the 500th case celebrated on April 25. The center’s long‑term memorandum of understanding with Meere supplies on‑site technical support and systematic clinical validation, ensuring safety and efficacy standards comparable to foreign competitors. Reaching the 500‑case threshold not only validates the platform’s reliability but also provides a robust data set for further refinements.

The milestone carries strategic weight for Korea’s health‑technology ecosystem. By proving that a locally produced robot can sustain high‑volume oncology work, KIRAMS paves the way for broader hospital adoption, potentially driving down procurement costs and fostering a domestic supply chain for parts and maintenance. Moreover, the success may attract venture capital and government incentives aimed at scaling export opportunities, positioning Korea as a credible alternative to established Western manufacturers. As more institutions consider robotic assistance, the Revo‑i achievement could accelerate a shift toward home‑grown solutions across Asia’s rapidly expanding medical markets.